痛泻要方联合马来酸曲美布汀治疗腹泻型肠易激综合征临床观察

目的：观察痛泻要方联合马来酸曲美布汀治疗腹泻型肠易激综合征的临床疗效和不良反应。方法：将本院收治的腹泻型肠易激综合征患者56例随机分为研究组和对照组，每组各28例。研究组给予痛泻要方，每日l剂，马来酸曲美布汀分散片200mg，每日3次；对照组仅服用马来酸曲美布汀分散片200mg，每日3次，两组均治疗6周。观察两组患者临床疗效和不良反应。结果：研究组痊愈5例，显效9例，有效8例，总有效率为78．6％；对照组痊愈3例，显效6例，有效4例，总有效率为46．4％，研究组总有效率明显高于对照组（P〈O．05）。两组患者治疗过程中均无明显不良反应，均完成治疗。结论：痛泻要方联合马来酸曲美布汀治疗腹泻型肠易激综合征临床疗效肯定，不良反应较小，疗效明显优于单一应用马来酸曲美布汀治疗。

A Clinical Observation of Tongxieyaofang Combined with Trimebutine Maleat in Treatment of Diarrhea-predominant Irritable BowelSyndrome~

Objective： To observe the clinical efficacy and adverse reactions of Tongxieyaofang combine with TrimebutineMaleat treatment for diarrhea-predominant irritable bowel syndrome.Method： 56 patients of diarrhea-predominant irritable bowel syndrome were randomly divided into the study group and the control group, 28 cases in each group. The study group was given Tongxieyaofang, TrimebutineMaleat, 200 mg, 3 times a day; the control group, only taking TrimebutineMaleat, 200 mg three times a day, both for 6 weeks. The clinical efficacy and adverse reactions were observed. Result： The study group recovered was 5 cases, the total effective rate was 78.6%; the control group recovered 3 cases, the total effective rate of 46.4%, the total efficiency of study group was significantly higher （ P〈0.05 ） .No significant adverse reactions during the treatment of the two groups of patients completed the treatment.Conclusion： Tongxieyaofang combine with TrimebutineMaleat treatment of diarrhea-predominant irritable bowel syndrome clinical efficacy certainly less adverse reactions, significantly better than a single application TrimebutineMaleat treatment.